Introduction
T he clinical use of the so-called ''novel cellular therapies,'' namely those not aimed at the reconstitution of the hematopoietic system, is not only a challenging target for the scientific community, but also the subject of intense public debate. 1, 2 The landscape includes not only the scientific and clinical community together with the patients, their families, and the lay public, but also health regulators, national health services/health insurance companies, and service providers. Despite the direct interest by a broad set of involved parties, transparent access to accurate data on clinical use of cell therapies is extremely limited and confined within specific sectors.
In 2008, the European sections of the Tissue Engineering and Regenerative Medicine International Society-Europe (TERMIS-EU), of the International Society of Cellular Therapy (ISCT), and of the International Cartilage Repair Society (ICRS), in a joint initiative with the European group for Blood and Marrow Transplantation (EBMT) and the European League Against Rheumatism (EULAR), established a survey on novel cellular therapies. This has allowed the number of patients treated in Europe with cells or engineered tissues to be collected and to be sorted by specific therapeutic indications, cell types used, and cell processing/delivery modes. [3] [4] [5] The survey aims to offer a transparent and unbiased update on the constructive work carried out, thanks to the coordinated efforts of the different stakeholders, including scientists, clinicians, and their patients, in compliance with the required authorizations.
Here, we report the results of the fourth survey for the activity in 2011, with a comparison to the previously identified trends and a specific discussion on cell-based treatments in the field of cardiovascular therapy. The information presented is complementary to that available in published studies and public databases (e.g., www.clinicaltrials.gov), as it does not include safety/efficacy data and specifies the conducted as opposed to planned numbers of treatments.
Patients and Methods

Definitions
For the purpose of this survey, novel cellular therapies include the use of cells other than hematopoietic stem cells (HSC) or of HSC for uses other than reconstitution of the hematopoietic system. The term HSC, which is often ambiguously used in the field of novel cellular therapies, here indicates a mixture of stem and progenitor cells predominantly of the hematopoietic lineage. Donor lymphocyte infusions often used in relapsing patients after HSC transplantation are considered to be an integral part of the HSC transplant procedure and are excluded.
Data collection and validation
Participating teams were requested to report their data for 2011 by indication, cell type and source, donor type, processing method, and delivery mode. The survey followed the traditional principles of the EBMT, concentrating on numbers of patients with a first cellular therapy. EBMT teams from 49 countries (39 European and 10 affiliated countries) were contacted for the 2011 report (EBMT survey), as were members of the 4 participating societies, teams who had reported activity to previous surveys, together with 118 additional contacts identified either through the clinicaltrials.gov database or literature search. The non-European countries affiliated with the EBMT were Algeria, Azerbaijan, Iran, Israel, Jordan, Lebanon, Nigeria, Saudi Arabia, South Africa, and Tunisia. Extended questionnaires, in the format displayed in Supplementary Table S1 (Supplementary Data are available online at www.liebertpub.com/tea), were received in paper form or electronically. Quality control measures, for EBMT members only, included several established independent systems: confirmation of validity of the entered data by the reporting team, selective comparison of the survey data with MED-A data sets in the EBMT ProMISE data system, cross-checking with the National Registries, and onsite visits of selected teams. No quality control system could be applied to the non-EBMT reporting teams as yet.
For this survey, a number of changes in the data collection sheet were introduced (i) to better capture and group the disease indications and (ii) to distinguish between automated and manual cell processing. In the accompanying guidelines, automated cell processing was described as being appropriate when the cell isolation or culture was performed using an automated device.
Transplant rates
Transplant rates, defined as the reported numbers of patients receiving cellular therapies or the number of teams reporting treatments per 10 million inhabitants, were computed for each country, without adjustments for patients who crossed borders or received treatment in a foreign country. Population numbers were obtained from the 2011 US census office database (www.census.gov).
Results
Participating teams
Two hundred forty-six teams in 35 countries (29 European and 6 EBMT affiliated countries) responded to the novel cellular therapy survey, 126 teams (24 countries) reported performing novel cellular therapies providing detailed information on indication, cell source and type, donor type, processing, and delivery mode, whereas 120 teams reported no activity. In previous years, a number of teams have reported using the standard EBMT transplant activity survey sheet, allowing the inclusion of limited information. This year, for the first time, all EBMT teams reporting information on cellular therapies completed the extended questionnaire.
Teams that responded to the activity are listed in Appendix in alphabetical order by country, city, EBMT CIC code (if applicable), along with the total numbers of reported novel cellular therapies.
indication: autologous cells were used predominantly for musculoskeletal/rheumatological (58%) and cardiovascular (27%) disorders, whereas the main use of allogeneic cells was for hematology/oncology (84%) (Fig. 1 ). MSC were mainly obtained from adipose tissue (50%) or bone marrow (49%) and mostly used for the reconstructive surgery/tissue enhancement within the area of musculoskeletal/rheumatological disorders (54%) or for hematology/oncology (31%). For the HSC treatments, cells were derived from bone marrow (65%) or peripheral blood (35%).
The percentage of treatments using autologous versus allogeneic cells steadily increased from 36% in 2008 to 79% in CELLULAR THERAPY ACTIVITY SURVEY 2011 3
2011. This was reflected in the trends for the various therapy areas, with the exception of hematology/oncology (Fig. 2) .
Cell processing and delivery mode
Of all the grafted products, 65% required cell expansion, 3% were transduced cells, and 10% were sorted (Table 2) . Nonexpanded cells were used to treat 95% of cardiovascular, 70% of musculoskeletal/rheumatological, and 63% of neurological indications, while gastrointestinal indications were exlusively treated with expanded cells. Expanded cells were also used for 97% of hematology/oncology treatments. Cell sorting was applied predominantly for musculoskeletal/ rheumatological (10%) and cardiovascular (10%) disorders. Transplanted cells were genetically transduced for 58% of solid tumor cases, 21% of gastrointestinal (all liver insufficiency), and 6% of cardiovascular diseases. Twenty-four percent of cells were reported to be processed using an automated device. These cells were mostly used to treat cardiovascular (39%), musculoskeletal/rheumatological (25%), or gastrointestinal (21%) diseases.
Just under one half (42%) of the cell grafts was delivered intra-organ, 26% intravenously, 16% on a membrane or gel, and 16% using a 3D scaffold (Table 3) . Cells were delivered intra-organ for 66% of cardiovascular, 58% of neurological, and 50% of musculoskeletal/rheumatological disorders. Intravenous delivery was reported for all hematology/oncology treatments and about half (47%) for gastrointestinal disorders. The use of a membrane or a gel for cell delivery was reported almost exclusively for musculoskeletal/rheumatological (33%) treatments. A 3D scaffold was used for musculoskeletal/rheumatological indications (16%), in particular for cartilage or bone repair (42%) and for cardiovascular (21%) disorders-within this mainly for decubitus and leg ulcers (74%).
Transplant rates and active teams
Reported cellular therapies were performed in a limited number of countries and with different intensity. Figure 3 displays the reported cellular therapy transplants per 10 million inhabitants in the different European-and EBMTassociated countries. High transplant rates (i.e., > 100 per 10 million population) were reported in Italy and Slovenia. The number of teams reporting novel cellular therapies was also mapped in the different European-and EBMT-associated countries after normalization to the inhabitant numbers (Fig.  4) . The number of reporting teams per 10 million inhabitants was higher than four in Belgium, Israel, The Netherlands, Slovenia, Spain, and Switzerland. 
Discussion
The data collected in the fourth edition of the novel cellular therapy survey indicate a further increase compared to the previous year in the number of reporting teams ( + 19%), of total treatments reported ( + 39%), and of total treatments reported using the dedicated form ( + 74%). These results indicate that, thanks to the networks of the involved societies and the introduced strategy of head-hunting for known active teams, the program is receiving a growing recognition as a reference platform to collect and disseminate information that is not available in public databases or scientific publications. Moreover, the comparative analysis of data generated in the four surveys [3] [4] [5] allows the identification of some established features and developing trends.
The steady increase in the percentage of treatments using autologous versus allogeneic cells is possibly due to a combination of cultural, regulatory, and/or commercial issues. Due to the oft claimed ''minimal manipulation'' and ''homologous use'' of the cells, the use of nonexpanded autologous MSC for reconstructive surgery/tissue enhancement is considered by some as ''tissue transplantation'' rather than ''biological drug,'' and therefore not subject to the same rigorous regulatory framework as are expanded MSC. This distinction may become somewhat artificial, as shown recently in the Celltex case. 6 The number of treatments for GvHD prevention or treatment remained relatively stable throughout the 4 years (from 240 in 2008 to 265 in 2011), possibly due to the combination of increasing encouraging phase I/II data, 7 but there is a lack of conclusive data from adequately powered, prospective randomized controlled (PRC) trials.
The most obvious changes in the indications addressed were in the important introduction of nonexpanded MSC (predominantly freshly harvested from autologous adipose 6  16  22  14  24  2  36  Other  21  37  58  58  9  49  Total  1050  709  1708  51  1578  181  382  1377 CELLULAR THERAPY ACTIVITY SURVEY 2011tissue) for plastic and reconstructive surgery, as well as for decubitus and leg ulcers (total of 440 treatments). In this regard, evidence of efficacy is still limited to case reports and small series at this stage. 8, 9 It is thus vital that PRC clinical trials are carried out in the next years to demonstrate a statistical superiority of outcome for the cell-based versus cell-free treatments. The trend in the cell delivery mode was rather stable: the exception is of a fourfold increase in the percentage of use of 3D scaffolds, mostly associated with cartilage/bone repair treatments, skin reconstruction, and ulcers.
This year, for the first time, the data collection for cell processing included a query of whether cell graft manufacturing included a step performed with an automated system. Although the definition of ''automation'' could be interpreted differently by the responding teams, and respondents did not specify whether the system was closed or streamlined with the rest of the manufacturing line, it is nonetheless remarkable that 22% of the total treatments were claimed to involve an automated process. A closer analysis of the associated cell sources indicates that an automated device was introduced predominantly for the direct implantation of freshly harvested, autologous cells. The collected data are consistent with the commercial availability of systems for the device-assisted isolation or concentration of HSC (e.g., Sepax; Biosafe SA, www.biosafe.ch), of adiposederived cells (e.g., Celution Ò ; Cytori, www.cytori.com) or of bone marrow-derived MSC (e.g., Reamer Irrigator Aspirator; Synthes, www.synthes.com). This year's edition offers a perspective on cardiac cell therapy, in an attempt to complement the collected data with those available from other sources. Cardiovascular disease represents a leading disease worldwide associated with a high morbidity and mortality. 10 Current therapeutic options for patients suffering from heart failure due to myocardial infarction or other cardiomyopathies comprise medical treatment, ventricular assist devices, and heart transplantation. However, although heart transplantation has emerged as the standard of care and the only curative treatment for these patients, the key problem of organ shortage-while patient numbers continually rise-remains. In line with regenerative strategies in other medical fields, the concept of cardiac stem cell therapy has created substantial hope for the treatment of heart failure due to myocardial infarction and other cardiomyopathies. 11 Therefore, numerous experimental and preclinical animal studies have been performed in the past decade 12 utilizing a wide range of different adult stem cells. These include different subpopulations of bone marrow-derived progenitors, skeletal myoblasts, adipose-tissue derived MSC, prenatal progenitors, blood-derived progenitors as well as the recently discovered cardiac-resident stem cells. [13] [14] [15] [16] [17] [18] [19] In addition, embryonic stem cells or induced pluripotent cells have been shown to be able to differentiate into functional cardiomyocytes and are in the focus as a potential cell source. 20 Based on promising preclinical data, various cell types have already progressed into use in clinical pilot studies primarily aiming at demonstrating feasibility and safety in patients suffering from acute myocardial infarction, chronic heart disease/refractory angina, as well as ischemic cardiomyopathy. 18, [21] [22] [23] [24] [25] Bone marrow-derived progenitors represent the most frequently used cell source. Historically, Prof. Bodo Strauer from the University of Dü sseldorf was, in 2001, the first to treat patients with acute myocardial infarction with intracoronary-infused bone marrow mononuclear cells (BMMC). 26 Based on this study, numerous cohort studies and randomized trials such as the BOOST study and the REPAIR-AMI trial have been performed, testing intracoronary infusion of bone marrow-derived progenitor cells for cardiac cell therapy. 21, 25, 27 While all study groups reported a sufficient safety profile for these cells, the results with regard to efficacy (i.e., improvement of ventricular function) are still under controversial discussion. A recent meta-analysis of 50 studies (with a total of 2625 patients) comprising mixed results of cohort studies and PRC trials demonstrated a significant, but still relatively limited (*4%) 
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improvement of left ventricular ejection fraction (LVEF) after BMMC therapy when compared to control patients. 28 In line with the collected data (Table 1) , the application of one subpopulation of BMMC, namely MSC, has been reported to be a valid and safe option for cardiac cell therapy. In contrast to BMMC, the use of MSC in smaller cohort studies has demonstrated a more pronounced effect on LVEF; this, however, needs to be confirmed in current PRC trials such as the TAC-HFT (TAC-HFT/ ClinicalTrials.gov Identifier: NCT00768066). In parallel, the utilization of adipose tissue-derived MSC has been investigated in several preclinical studies and has lead to the initiation of first clinical trials such as the APOLLO study (APOLLO/ClinicalTrials.gov Identifier: NCT0044 2806).
An interesting concept to enhance the efficacy and the cardiogenic potential of bone marrow-derived MSC is the concomitant application of a cardiopoietic cocktail. This has been shown to be feasible in a preclinical study 29 and has recently led to a pilot clinical study, the C-Cure trial, where the safety and importantly beneficial effect of cardiopoietic MSC could be demonstrated (C-Cure/ClinicalTrials.gov Identifier: NCT00810238) and was the basis for a randomized multicenter trial to be initiated.
Besides the utilization of BMMC or subpopulations thereof, the use of skeletal myoblasts has also been proposed as a potential cell source for myocardial repair and has advanced into numerous clinical studies such as the MAGIC trial 30 and others (MYOHEART/ClinicalTrials.gov Identifier: NCT00054678). However, while preclinical and initial clinical data showed promising results, the major problem with these cells is the lack of electrical coupling with the hosting myocardium. Due to a lack of gap junctions and connexins, the skeletal myoblast therapy led to severe arrhythmia in some individuals and raised significant safety concerns. However, to ensure patient safety, systematic antiarrhythmic medical therapy or implantable cardioverterdefibrillator implantation represent valid tools to treat affected patients. 31 Following the compelling evidence on the preclinical use of cardiac resident stem cells, two pilot clinical trials employing cardiac progenitors were recently initiated 22, 24 (CADUCEUS/ClinicalTrials.gov Identifier: NCT00893360; SCIPIO/ClinicalTrials.gov Identifier: NCT00474461). The promising preliminary results will need to be confirmed, in both the longer term and larger patient series.
Ten years after the first intracoronary clinical application of BMMC was reported, 32 the concept of cardiac cell therapy has continuously evolved over time utilizing different cell types and application routes (intracoronary vs. intramyocardial) in different clinical scenarios. While most of these studies have focused on feasibility and safety, more recently initiated trials are targeting assessment of the efficacy of cardiac cell therapy concepts. Although the body of clinical experience is continuously growing, several key issues and questions are pending. These include not only the definition of appropriate product release criteria and clinical endpoints but also of a suitable cell type, route, and time of application. In this regard, the reported data here offer the unique opportunity to capture trends and monitor changes in the field, in a way which reflects the conducted (as opposed to planned) number of treatments and which can be communicated before a full report is published and publicly available.
Geneva, Concept Clinic, KU. Schlaudraff (11; 0/11) Following the coordinated efforts of five established scientific organizations, this report describes the novel cellular therapy activity in Europe for the year 2010. One hundred six teams from 27 countries responded to the cellular therapy survey, 69 teams from 21 countries provided data on 1010 patients using a dedicated survey; 37 teams reported no activity. These data were combined with an additional 260 records reported by 37 teams in 15 countries to the standard European group for Blood and Marrow Transplantation (EBMT) database. Indications were graft-vs.-host-disease (GvHD; 26%; 11% autologous), musculoskeletal disorders (25%; 93% autologous), cardiovascular disorders (20%; 100% autologous), epithelial disorders (16%; 44% autologous), autoimmune diseases (11%; 55% autologous), and neurological disorders (2%; 62% autologous). Autologous cells were predominantly used for musculoskeletal (39%) and cardiovascular (32%) disorders, whereas allogeneic cells were mainly used for GvHD (58%) and epithelial disorders (23%). The reported cell types were mesenchymal stem/ stromal cells (MSC; 49%), hematopoietic stem cells (28%), chondrocytes (10%), dermal fibroblasts (4%), keratinocytes (1%), and others (8%). In 63% of the grafts, cells were delivered following ex vivo expansion, whereas cells were transduced or sorted respectively in 10% or 28% of the reported cases. Cells were delivered intraorgan (45%), intravenously (31%), on a membrane or gel (20%) or using 3D scaffolds (4%). Compared with last year, the number of teams adopting the dedicated survey was 1.25-fold higher and, with few exceptions, the collected data confirmed the captured trends. This year's edition specifically discusses scientific, clinical, regulatory, and commercial aspects related to the use of cell therapy for the repair of cartilage defects.
Introduction D espite the compelling clinical needs in regenerative medicine, the so-called novel cellular therapies, namely those not targeting the reconstitution of the hematopoietic system, have yet to result in products with a documented clinical benefit. It is worthwhile considering that in the field of bone marrow transplants, which represents the pioneering cellular therapy, it took almost 30 years from the first scattered clinical tests in the 1950s until hematopoietic stem cell (HSC) transplantation became the standard of treatment for hematologic malignancies, and refinements of the procedure continue to be investigated to improve the success rates. This short historical perspective indicates that clinical implementation of cellular therapy requires time and long-term efforts and that novel cellular therapies are still at an infancy stage. As for the field of bone marrow transplantation, progress in the field of novel cellular therapies is expected to require an open and coordinated communication of the ongoing trials, as a platform to carry out analyses of trends, successes, and failures. [1] [2] [3] [4] Information available in public databases (e.g., www .clinicaltrial.gov) is critical to establish a map of the planned or ongoing trials, but does not allow identifying the precise number of patients treated with specific cells at a defined point in time. Published results of clinical studies are keys to evaluate the primary endpoints, but only marginally represent the total number of performed trials. Databases organized by working groups on specific areas (e.g., by the European group for Blood and Marrow Transplantation [EBMT] ) have the main advantage of including data on the patient outcome, but can hardly be extended to the public domain, where sharing of critical information may conflict with confidentiality issues or commercial interests.
Since 2008, a complementary program has been established by the European sections of the Tissue Engineering and Regenerative Medicine International Society (TERMIS-EU), the International Society of Cellular Therapy (ISCT), and the International Cartilage Repair Society (ICRS) in a joint initiative with the EBMT and the European League Against Rheumatism (EULAR). 5, 6 The program is organized in the form of a survey, collecting the number of patients being treated in Europe by novel cellular therapies, sorted by specific therapeutic indications, cell types used, and cell processing/delivery modes. The absence of patient assessment data, the yearly publication of the data, and the possibility offered to the participating teams to query more specific information offers an open and flexible platform to establish and disseminate the status in the field of novel cellular therapies in Europe.
Here, we report the results of the third survey edition for the activity in 2010, with a comparison to the previously identified trends and a specific discussion on the field of cellbased cartilage repair procedures.
Patients and Methods
Definitions
For the purpose of this survey, novel cellular therapies include the use of cells other than HSC or of HSC for uses other than reconstitution of the hematopoietic system. The term HSC, which is often ambiguously used in the field of novel cellular therapies, indicates a mixture of stem and progenitor cells predominantly of the hematopoietic lineage. Donor lymphocyte infusions, often used in relapsing patients after HSC transplantation, are considered to be an integral part of the HSC transplant procedure and are excluded. The term ''Epithelial disorders'' is also used to include parenchymal diseases, as for example, diabetes or liver insufficiency.
Data collection and validation
Participating teams were requested to report their data for 2010 by indication, cell type and source, donor type, processing method, and delivery mode. The survey followed the traditional principles of the EBMT, concentrating on numbers of patients with a first cellular therapy. Members of the four participating societies from 47 countries (39 European and 8 affiliated countries) were contacted for the 2010 report (EBMT survey). The non-European countries affiliated with the EBMT were Algeria, Iran, Israel, Jordan, Lebanon, Saudi Arabia, South Africa, and Tunisia. For EBMT teams not using the extended questionnaire, information on cellular therapies was limited to numbers of HSC for nonhematopoietic use, mesenchymal stem/stromal cell (MSC)-based therapies (later identified to be almost exclusively related to treatment of graft-vs.-host-disease [GvHD]), and donor type. Extended questionnaires, in the format displayed in Supplementary Figure S1 (Supplementary Data are available online at www.liebertpub.com/tea), were collected by paper forms or electronically. Quality control measures, for EBMT members only, included several established independent systems: confirmation of validity of the entered data by the reporting team, selective comparison of the survey data with MED-A data sets in the EBMT ProMISE data system, crosschecking with the National Registries, and onsite visits of selected teams. No quality control system could be yet applied for the non-EBMT reporting teams.
Transplant rates
Transplant rates, defined as the reported numbers of patients receiving cellular therapies or the number of teams reporting treatments per 10 million inhabitants, were computed for each country, without adjustments for patients who crossed borders or received treatment in a foreign country. Population numbers were obtained from the 2010 U.S. census office database (www.census.gov).
Results
Participating teams
One hundred six teams in 27 countries (24 European and 3 affiliated countries) responded to the novel cellular therapy survey; 69 teams (21 countries) reported performing novel cellular therapies with detailed information on indication, cell source and type, donor type, processing, and delivery mode, while 37 teams reported no activity. The remaining 37 teams from 15 countries (13 European and 2 affiliated countries) reported using the standard EBMT transplant activity survey, allowing to include only limited information. Data were thus received from a total of 23 countries. Teams that responded with activity are listed in the Appendix in alphabetical order by country, city, and EBMT center code (if applicable), along with the total number of reported novel cellular therapies.
Number of novel cellular therapies and disease indications
According to the received reports, 1142 patients were treated with novel cellular therapies, 504 (40%) with allogeneic and 766 (60%) with autologous cells (Table 1) . Main indications were GvHD (26%; 11% autologous), musculoskeletal disorders (25%; 93% autologous), cardiovascular disorders (20%; 100% autologous), epithelial disorders (16%; 44% autologous), autoimmune diseases (11%; 55% autologous), and neurological disorders (2%; 62% autologous).
More detailed information on specific indications was obtained from 1010 patients. Among the musculoskeletal disorders, cartilage and bone repair were the most frequently reported indications. Among the cardiovascular disorders, peripheral artery disease, myocardial ischemia, and heart failure were the main reasons for a cellular therapy. Skin reconstruction, diabetes, and cornea repair were the three main reported indications for epithelial/parenchymal disorders. Among autoimmune disorders, gastrointestinal diseases and multiple sclerosis represented the predominant indications. The number of patients treated for neurological indications was rather limited and mostly confined to Huntington's disease. The number of reports of patients treated for GvHD needs to be combined with that reported in the EBMT standard form, for a total of 336 cases (Table 1) .
Cell type, source and donor type
Of the 353 HSC treatments, 93% were autologous transplants and 59% were used to treat cardiovascular CELLULAR THERAPY ACTIVITY SURVEY 2010diseases ( Table 1 ). All 125 chondrocyte transplants were autologous, whereas all 19 keratinocytes and 50 dermal fibroblasts transplants were allogeneic. Of 627 MSC-based therapies, 61% were allogeneic. The donor type was associated with the disease indication: autologous cells were predominantly used for musculoskeletal (39%) and cardiovascular (32%) disorders, whereas allogeneic cells were mainly used for GvHD (58%) and epithelial (23%) disorders (Fig. 1) . In the detailed survey, MSC were mainly obtained from bone marrow (63%) or adipose tissue (25%) and mostly used to treat GvHD (38%), musculoskeletal (31%), and autoimmune disorders (14%). For the HSC treatments, cells were derived from the bone marrow (90%) or peripheral blood (10%).
Cell processing and delivery mode
Of all the grafted products reported in detailed form, 63% required cell expansion, 10% were transduced cells, and 28% were sorted (Table 2 ). Nonexpanded cells were used to treat 83% of neurological, 82% of cardiovascular, 37% of intraorgan for 85% of cardiovascular, 58% of neurological, 49% of musculoskeletal, 40% of autoimmune, and 39% of epithelial disorders. Intravenous delivery was reported for all GvHD treatments and predominantly for autoimmune (60%), epithelial/parenchymal (21%), and cardiovascular (13%) disorders. The use of a membrane or a gel for cell delivery was reported almost exclusively for epithelial (39%) or musculoskeletal (38%) treatments. A 3D scaffold was used only for musculoskeletal indications (13%), in particular cartilage or bone repair.
Transplant rates and active teams
Reported cellular therapies were performed in a limited number of countries and with different intensity. Figure 2 displays the reported cellular therapy transplants per 10 million inhabitants in the different European and EBMTassociated countries. High transplant rates (i.e., > 100 per 10 million population) were reported in Belgium, the Republic of Belarus, Slovenia, and Switzerland. The number of teams reporting novel cellular therapies was also mapped in the different European and EBMT-associated countries after normalization to the inhabitant numbers (Fig. 3) . The number of reporting teams per 10 million inhabitants was higher than 4 in Belgium, Finland, Israel, Slovenia, and Switzerland.
Discussion
Compared with the data collected for patients treated in the previous years, 5, 6 the present report confirms the main identified trends, with a few remarkable differences. Although the percentages of treatments using autologous versus allogeneic cells were almost identical to those from 2008 and 2009, comparative analysis of specific categories indicates that the distribution of autologous or allogeneic cell transplantation for different indications has not yet reached a consolidated trend (Fig. 4) . The discrepancies are more .gov and summarized in a recent study. 7 The fact that most ongoing trials for cardiac-related disorders outside Europe use allogeneic cells 7 highlights that the present report may be not representative of a geographically global scenario for what concerns donor types within specific categories, probably due to a combination of cultural, regulatory, and/ or commercial issues. 
This year's focus: cell therapy for cartilage repair
In cartilage regeneration, the use of cell therapy has been established for over 20 years. 8, 9 This extensive experience has been beneficial to the cell therapy field as a whole to recognize the importance of identifying proper clinical indications and of validating the tools for outcome evaluation, and to experience the challenges of the treatments that are mainly economical and logistical. In Europe, cellular therapies were placed under the guidance of advanced therapeutical medicinal products by the EMA. The necessary trial data for registration have increased the current clinical knowledge and allowed more evidence-based treatment selection and development of well-established algorithms for patient profiling. 10, 11 The time between cartilage damage, the occurrence of symptoms and initiation of treatment is of direct influence on treatment outcome. 12 So-called ''old defects'' in a chronic stage, treated in an environment of disturbed joint homeostasis, show significantly worse clinical outcome at 5-year follow-up. Thus, the initial concept of applying cell therapy after failure of other treatments is being replaced by earlier intervention with application of advanced imaging methods for more active early diagnosis.
Since the new regulatory pathway and framework have been established in 2008, the first product has been approved (ChondroCelect; Tigenix, Leuven, Belgium) and others are in the process of acquiring such approval (MACI, Genzyme; Sanofi, Kopenhagen, Denmark). The next step will be to place these products within a clinical setting that most effectively exploits them. Given the general economic challenges in Europe, it seems clear that innovative healthcare solutions need to take into account the economic downturn and associated financial restrictions of healthcare systems. More and more we will be asked to apply innovative solutions in an initially limited market, to generate well designed prospective cost benefit and risk analyses. This will be most likely applied in selected cell therapy centers and should be providing data to a central European prospective registry (i.e., ICRS EuroCart), which will allow for reporting collaboratively on the outcome of these essential developments.
The data from the current survey indicate a rise from 7% in 2009 to 21% in 2010 in the use of nonexpanded cells. This seems to be a signal of the desire to limit the complexity and the morbidity of two-stage surgical procedures. The development of one-stage procedures alleviates the need for double surgery and extensive waiting time between biopsy and graft delivery. Currently, only autologous chondrocytebased therapy has a clinically proven track record. However, the focus is shifting toward the use of MSCs from diverse sources to be applied in one-stage procedures with or without addition of growth factors, bone marrow concentrates, and other cell types and/or biomaterials. 13 Another interesting observation from this survey is the use of membranes or gels as delivery substances. Their rise from 12% in 2009 to 38% in 2010 clearly demonstrates the increased acceptance of biomaterials but may also reflect the demand for higher reliability of delivery, appropriate cell dosing, and possibly arthroscopic or minimally invasive graft delivery, for which injectables or synthetic carriers are essential. These changes will progress most likely to a level where injectable and malleable biomaterials will be used in all procedures, replacing the need for additional harvesting of patient's own tissue (e.g., periosteal flap) for the application of the cell product.
What will be the next developments in cell-based cartilage repair? The application of cell therapy to the treatment of critically sized defects or in osteoarthritis is a great challenge and would have considerable impact on the field. 14, 15 Another challenge is the need to establish registered products for specific indications based on multiple prospective randomized trials and in turn to address the large financial and regulatory burden these trials produce. The associated risk is to slow down the implementation of innovation and to exclude the smaller initiatives, thus creating a bias toward large pharmaceutical companies, which may or may not be desirable. Broader and more standardized clinical trials/use of cell-based grafts will require to introduce manufacturing paradigms inspired from other well-established biotechnology sectors, for example an automated production within
FIG. 4. Comparative analysis of indications for novel cellular therapies in
Europe from 2008 to 2010, sorted by donor type. Data used for this chart were derived from the current study and the two previous reports. 5, 6 closed bioreactor systems. 16 Finally, a European harmonization of guidelines of eligibility for reimbursement by health insurances will have to be targeted. Most professional orthopedic organizations agree on a clinical treatment algorithm for cartilage defects and this professional consensus should be the guide for policy makers and healthcare providers.
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Conclusions
The progressive increase in the number of reporting teams using the dedicated form and the number of total treatments being claimed (respectively 25% and 11% from the previous year) indicates that the inter-society program of the survey on novel cellular therapies is becoming a reference platform for access to information that is not available in public databases or scientific publications. Nevertheless, we are aware that several active teams in Europe have not reported treatments and therefore, the data in this survey represent an underestimation of the actual number of novel cellular therapies and groups involved. The use of a more organically structured query form, which has been introduced for the collection of 2011 data, together with the planned headhunting for active teams not yet reporting treatments, are expected to further consolidate the program. Moreover, while published and registered studies provide a complementary type of information, released with a different timing as compared with this survey, we expect that only an integrated use of the different instruments will allow to effectively monitor changes and trends in cell-based therapeutic strategies.
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17. Saris, D.B., Buma, P., and Bulstra, S.K. 4 Thanks to the coordinated efforts of four major scientific organizations, this report describes the ''novel cellular therapy'' activity in Europe for the year 2009. Fifty teams from 22 countries reported data on 814 patients using a dedicated survey, which were combined to additional 328 records reported by 55 teams to the standard European Blood and Marrow Transplantation (EBMT) database. Indications were cardiovascular (37%; 64% autologous), graft-vs.-host disease (27%; 7% autologous), musculoskeletal (17%; 98% autologous), epithelial/ parenchymal (8%; 73% autologous), autoimmune (9%; 84% autologous), or neurological diseases (3%; 50% autologous). Autologous cells were used predominantly for cardiovascular (42%) and musculoskeletal (30%) disorders, whereas allogeneic cells were used mainly for graft-vs.-host disease (58%) and cardiovascular (30%) indications. Reported cell types were mesenchymal stem/stromal cells (MSC) (46%), hematopoietic stem cells (27%), chondrocytes (7%), keratinocytes (5%), dermal fibroblast (13%), and others (2%). In 59% of the grafts, cells were delivered after expansion; in 2% of the cases, cells were transduced. Cells were delivered intraorgan (46%), on a membrane or gel (29%), intravenously (16%) or using 3D scaffolds (8%). As compared to last year, the number of teams adopting the dedicated survey was 1.7-fold higher, and, with few exceptions, the collected data confirmed the captured trends. This year's edition specifically describes and discusses the use of MSC for the treatment of autoimmune diseases, due to the scientific, clinical, and economical implications of this topic. 1 was an extension of the well-established EBMT annual report, an instrument to observe trends and to monitor changes in the use of HSC transplants for the treatment of hematologic disorders in Europe. 2, 3 The activity survey does not provide any data on specific protocols, outcome, age, or sex of patients or their pre-and post-transplant therapy. The goal of the data collection is the rapid dissemination of the status in the field of novel cellular therapies, identifying trends related to covered indications, as well as specific cell types, cell processes, and delivery modes used. Long-term analyses of the EBMT survey provided evidence that the instrument can foresee trends with high predictability and very rapidly (e.g., the increasing use of cord blood as a stem cell source, the change from bone marrow to peripheral blood or the utilization and integration of unrelated donor transplants 4, 5 ) and can thus provide a formal basis for patient counseling and healthcare planning.
In this article, we report the results of the second survey edition for the activity in 2009, with a direct comparison to the 2008 data reported last year and specifically discussing the use of mesenchymal stem/stromal cells (MSC) for the treatment of autoimmune diseases.
Patients and Methods
Data collection and validation
Participating teams were requested to report their data for 2009 by indication, cell type and source, donor type, processing method, and delivery mode. The survey followed the traditional principles of the EBMT, concentrating on numbers of patients with a first cellular therapy. For EBMT teams not using the full questionnaire, information on cellular therapies was limited to numbers of HSC for nonhematopoietic use, MSC-based therapies (later identified to be almost exclusively related to treatment of graft-vs.-host-disease), and donor type. Questionnaires were collected by paper forms or electronically. Quality control measures, for EBMT members only, included several established independent systems: confirmation of validity of the entered data by the reporting team, selective comparison of the survey data with MED-A data sets in the EBMT ProMISE data system, cross-checking with the National Registries and onsite visits of selected teams. No quality control system could be applied for the non-EBMT reporting teams yet.
Teams
Members of the four participating societies from 47 countries (39 European and 8 affiliated countries) were contacted for the 2009 report (EBMT survey). The nonEuropean countries affiliated with the EBMT were Algeria, 
Transplant rates
Transplant rates, defined as numbers of cellular therapies per 10 million inhabitants, were computed for each country, without adjustments for patients who crossed borders or received treatment in a foreign country. Population numbers were obtained from the U.S. census office database (www.census.gov).
Results
Number of novel cellular therapies and disease indications
According to the received reports, a total of 1142 patients were treated with novel cellular therapies, 496 (43%) with allogeneic and 646 (57%) with autologous cells (Table 1) . Main indications were cardiovascular disorders (37%; 64% autologous), graft-vs.-host disease (27%; 7% autologous), musculoskeletal disorders (17%; 98% autologous), autoimmune diseases (9%; 84% autologous), and epithelial (8%; 73% autologous) and neurological disorders (3%; 50% autologous).
From 814 patients, more detailed information was obtained concerning indications. Among the cardiovascular disorders, decubitus and leg ulcers (n = 150), myocardial ischemia (n = 111), peripheral artery disease (n = 56), and heart failure (n = 33) were the most frequently reported indications. Among the musculoskeletal disorders, cartilage repair (n = 91) and bone repair (n = 68) were the main reason for a cellular therapy. Skin reconstruction (n = 51) and cornea repair (n = 27) were the two main reported indications for epithelial/parenchymal disorders. Neurological indications were only performed for disorders not included in the form (n = 16, 8 of which for glioblastoma). Among autoimmune disorders, neurological diseases (n = 70), including multiple sclerosis, represented the predominant indication. The number of reports of patients treated for graft versus host disease (n = 19) needs to be combined with that reported in the EBMT standard form, for a total of 307 cases (Table 1) .
Cell type, source, and donor type Of the 304 HSC treatments, 95% were autologous transplants and 80% were used to treat cardiovascular diseases (Table 1 ). All 82 chondrocyte and 51 keratinocytes transplants were autologous and the 150 dermal (100 of which of fetal origin) fibroblasts transplants were allogeneic. Of the 520 MSC based therapies, 59% were allogeneic. The donor type was associated with the disease indication: autologous cells were used predominantly for cardiovascular (42%) and musculoskeletal (30%) disorders, whereas allogeneic cells were used mainly for graft-vs.-host disease (58%) and cardiovascular (30%) indications (Fig. 1 ). In the detailed survey, MSC were obtained from bone marrow in 219 (94%) cases and mostly used to treat autoimmune (53%), musculoskeletal (31%), and cardiovascular disorders (14%). For the 264 HSC treatments, cells were derived from the bone marrow (85%), peripheral blood (8%), placenta (5%), or unspecified cell source (2%).
Cell processing and delivery mode
Of all the grafted products reported in detailed form, 59% were based on expanded cells and in 2% of the cases cells were transduced (Table 2) . About one half (48%) of the products was given intraorgan, 29% on a membrane or gel, 14% intravenously, and 8% using a 3D scaffold. Nonexpanded cells were used to treat 55% of cardiovascular, 38% of musculoskeletal, 38% of epithelial/parenchymal, and 31% of neurological disorders, whereas autoimmune diseases were exclusively treated with expanded cells. Cell sorting was operated for 69% of neurological, 11% of epithelial, 11% of cardiovascular, and 1% of musculoskeletal disorders. Beyond a few sporadic exceptions, reported for cardiovascular, musculoskeletal, and neurological diseases, transplanted cells were not genetically transduced.
For neurological and autoimmune applications, cells were delivered exclusively intravenous or intraorgan ( Table 3) . The use of a membrane or a gel for cell delivery was reported mainly for cardiovascular treatments (63%), epithelial/parenchymal treatments (33%), or for cartilage repair (5%). For the group of musculoskeletal indications, all possible cell delivery modes were reported, with a predominant tendency for intraorgan (57%) and for the use a 3D scaffold (36%).
Transplant rates and active teams
Reported cellular therapies were performed in a limited number of countries and with different intensity. Figure 2 displays the cellular therapy transplant rates per 10 million inhabitants in the different European & EBMT-associated countries. High transplants rates (i.e., 40 per 10 million population) were reported in Belgium, Greece, Israel, the Netherlands, Norway, Slovenia, and Switzerland. The number of teams reporting cellular therapies was also mapped in the different European & EBMT-associated countries after normalization to the inhabitant numbers (Fig. 3) . The number of active teams per 10 million inhabitants was higher than 4 in Belgium, Greece, Israel, Lebanon, and Slovenia.
Discussion
The intersociety program of the survey on novel cellular therapies represents a unique opportunity for early access to information that integrates that available in public databases (e.g., www.clinicaltrial.gov) and that will only partially and at later times be published in the scientific literature. The 1.7-fold increase in the number of participating teams within Europe and associated countries as compared to the past year demonstrates the raising interest in the program and is expected to stimulate the contribution by other groups and societies in the next years. In this regard, the list of reporting centers in the manuscript Appendix is far from being exhaustive of the effective status, but has the potential to become a key reference for the field.
As compared to the data collected for patients treated in the previous year, 1 the present report confirms the main identified trends, though with few remarkable differences, especially related to the cardiovascular diseases. For the latter indications, the number of total treated cases increased by 1.4-fold, with a 7.0-fold higher percentage for peripheral artery disease and a 1.7-fold lower percentage for myocardial ischemia. In the same category of cardiovascular disorders, the cell source shifted from entirely autologous to allogeneic in 36% of the cases, with an increase from 8% to 45% in the use of expanded cells and the introduction of a membrane or gel delivery vehicle in 37% of the treatments. The changing variety of approaches tested may be considered as a sign that several key issues still need to be settled in that field, including the optimal cell type, source and dosing, the most effective route for cell transfer, and methods for enhancing survival of the cellular graft. 6 The most uniform category within those analyzed was the one targeting autoimmune disorders. The cells used were uniquely expanded MSC, untransduced, unsorted, and delivered intravenously (19%) or intraorgan (80%). The use of MSC in modulating autoimmune diseases is an emerging area of activity in cellular therapy. 7 Based on positive animal model data and in vitro demonstration of an Despite the inherent difficulties associated with the collection and management of data across different geographical areas, for the years to come efforts should be directed at coordinated initiatives toward the establishment of a global survey and report. several relevant features of the novel cellular therapy transplants (e.g., those related to the cell processing and delivery mode). Moreover, since those grafts are frequently performed outside the traditional hematology units, it became apparent that involvement of additional working groups was necessary to increase the relevance of the program.
In 2008, the European sections of the Tissue Engineering and Regenerative Medicine International Society (TERMIS-EU), of the International Society of Cellular Therapy (ISCTEurope), and of the International Cartilage Repair Society (ICRS) have for the first time coordinated a joint initiative with the EBMT and the European League Against Rheumatism (EULAR) to establish a comprehensive, quantitative map of patients being treated in Europe with specific cell types, sorted by the cell processes, and delivery modes used. In this article, we report the results of the first survey for the activity in 2008 and provide a perspective for a further extended and consolidated program for the years to come.
Patients and Methods
Data collection and validation
Participating teams were requested to report their data for 2008 by indication, cell type and source, donor type, processing method, and delivery mode. The survey followed the traditional principles of the EBMT, concentrating on numbers of patients with a first cellular therapy. For EBMT teams not using the full questionnaire, information on cellular therapies was limited to numbers of HSC for nonhematopoietic use, mesenchymal stromal cell-based therapies (later identified to be exclusively related to treatment of graft-versus-host disease), and donor type. Questionnaires were collected by paper forms or electronically. Quality control measures, for EBMT members only, included several established independent systems: confirmation of validity of the entered data by the reporting team, selective comparison of the survey data with MED-A data sets in the EBMT ProMISE data system, cross checking with the National Registries, and onsite visits of selected teams. No quality control system could be applied for the non-EBMT reporting teams yet.
Teams
Members of the 4 participating societies from 47 countries (39 European and 8 affiliated countries) were contacted for the 2008 report (EBMT survey). The non-European countries affiliated with the EBMT were Algeria, Iran, Israel, Jordan, Lebanon, Saudi Arabia, South Africa, and Tunisia. Thirtythree teams in 16 countries (14 European and 2 affiliated countries) reported novel cellular therapies using the survey form, with detailed information on indication, cell source and type, donor type, processing, and delivery mode. Additional 58 teams from 21 countries (19 European and 2 affiliated countries) reported treatments using the standard EBMT activity survey, allowing to include only limited information. Responding teams are listed in the Appendix in alphabetical order by country, city, and EBMT center code (if applicable), along with the total numbers of reported cellular therapies. According to the information received, there were no cellular therapies (including HSC transplants) performed in Albania, Andorra, Armenia, Georgia, Liechtenstein, Malta, Moldavia, Monaco, Montenegro, San Marino, and The Vatican in 2008.
Transplant rates
Transplant rates, defined as numbers of cellular therapies per 10 million inhabitants, were computed for each country, without adjustments for patients who crossed borders or received treatment in a foreign country. Population numbers were obtained from the U.S. Census Office database (www .census.gov).
Results
Number of novel cellular therapies and disease indications
According to the received reports, a total of 1040 patients were treated with novel cellular therapies, 376 (36%) with allogeneic and 664 (64%) with autologous cells (Table 1) . Main indications were cardiovascular disorders (29%; 100% autologous), musculoskeletal disorders (18%; 97% autologous), neurological disorders (9%; 39% autologous), epithelial disorders (9%; 18% autologous), autoimmune diseases (12%; 77% autologous), and graft-versus-host disease (23%; 13% autologous).
From 656 patients, more detailed information was obtained concerning indications. Among the cardiovascular disorders, myocardial ischemia (n ¼ 185), bypass grafts (n ¼ 43), and cardiomyopathy (n ¼ 13) were the most frequently reported indications. Among the musculoskeletal disorders, cartilage repair (n ¼ 90) and bone repair (n ¼ 24) were the main reason for a cellular therapy. Skin reconstruction (n ¼ 36) and liver insufficiency (n ¼ 11) were the two main reported indications for epithelial/parenchymal disorders. Neurological indications only included unspecified disorders (n ¼ 36). About 127 (19%) of all cellular therapies were for autoimmune disorders; in this category, multiple sclerosis (n ¼ 77) was the leading subgroup, followed by other neurological indications (n ¼ 20).
Cell type, source, and donor type
Of the 406 HSC treatments, 84% were autologous transplants and 70% were used to treat cardiovascular diseases (Table 1 ). All 48 chondrocyte and 16 myoblast transplants were autologous. Of the 491 mesenchymal stromal cellbased therapies, 49% were allogeneic.
In the detailed survey, mesenchymal stromal cells were obtained from bone marrow in all 251 cases and mostly used to treat musculoskeletal (33%), neurological (12%), and autoimmune disorders (51%). For the 262 HSC treatments, cells were derived from the bone marrow (70%), placenta (3%), and peripheral blood (27%). The donor type was associated with the disease indication: autologous cells were used predominantly for cardiovascular (47%) and musculoskeletal (25%) disorders, whereas allogeneic cells were used exclusively for autoimmune (72%) and epithelial/parenchymal (28%) indications (Fig. 1) .
Cell processing and delivery mode
Of all the grafted products reported in detailed form, 51% were based on expanded cells and in 5% of the cases cells were transduced (Table 2 ). About one-third (31%) of the products was given intravenously, 45% intraorgan, 14% on a membrane or gel, and 10% using a three-dimensional scaffold. The numbers on autoimmune diseases treated with hematopoietic stem cells (gray fields) are included in the standard EBMT survey report, along with other hematologic diseases.
a Numbers were imported from the limited questionnaire included in the standard EBMT survey sheet.
BM, bone marrow; Plac, placenta; CB, cord blood; PB, peripheral blood; Allo, allogeneic; Auto, autologous; N.S., not specified; EBMT, European Group for Blood and Marrow Transplantation.
Nonexpanded cells were used to treat 93% of cardiovascular, 50% of musculoskeletal, and 19% of neurological disorders, whereas epithelial/parenchymal and autoimmune diseases were exclusively treated with expanded cells. Beyond a few sporadic exceptions, mostly reported for cardiovascular and musculoskeletal diseases, transplanted cells were not genetically transduced or sorted. For cardiovascular, neurological, and autoimmune applications, cells were delivered exclusively intravenous or intraorgan ( Table 3 ). The use of a membrane or a gel for cell Data only from extended questionnaire.
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delivery was only reported for epithelial/parenchymal treatments (12%) or for cartilage repair (2%). For the group of musculoskeletal indications, all possible cell delivery modes were reported, with a predominant tendency (46%) to use a three-dimensional scaffold.
Cellular therapy rates
Reported cellular therapies were performed in a limited number of countries and with different intensity. Figure 2 displays the cellular therapy rates per 10 million inhabitants in the different European countries. High cellular therapy rates were reported in Belgium, the Netherlands, Slovenia, Switzerland, and Turkey.
Discussion
The study describes an extension of the previously consolidated EBMT annual activity report, to cover the field of the so-called ''novel cellular therapies,'' namely, the use of nonhematopoietic cells or of HSC for nonhematological indications. The program is still at the experimental stage, and it clearly did not include several teams active in the field of cellular therapy in Europe. Despite this expected initial limit, the initiative provided useful information on some of the trends related to cell-based treatment of various diseases in 2008, which could hardly be captured by analysis of scientific literature.
The survey does not include data on specific indications or patient outcome, and thus the aims are clearly distinct form those of a patient registry. Although the generated map does not offer the possibility of a scientific analysis, the simple structure of the platform and the absence of intellectual property or commercial issues should encourage the contribution by most academic and commercial groups. In this regard, we deem as a remarkable outcome that already five consolidated and large societies have joined forces toward the establishment of the program. Overall, the presented data highlight a relatively large activity in the clinical use of cell therapies, even in areas where scientific data have not yet established a benefit for the patient. To consolidate and further extend this initiative, additional working groups will be invited to participate. Moreover, it will be made more clear that reports for novel cellular therapies will all have to be claimed using the detailed form as opposed to the standard EBMT one. Next year's report, based on cell-based therapies performed in 2009, should thus more thoroughly capture the effective patient numbers and the modes of cell processing and delivery. This European program is also expected to stimulate parallel activities in other geographical areas, including the North American, Asian-Pacific, and economically emerging countries.
